Name: Abliva’s CEO: We are the leading programme in mitochondrial disease
Uploaded: 2024-08-26T08:45:23+02:00
Channel: Michael Jewett
Description: The positive interim phase II data with its lead candidate KL1333 has increased interest among investors and potential partners for Abliva

Abliva’s CEO: We are the leading programme in mitochondrial disease

26 augusti, 2024

Nyhetssvepet tisdag 17 september

17 september, 2024

Tag: Abliva FALCON study

Abliva’s CEO: We are the leading programme in mitochondrial disease

Nyhetssvepet tisdag 17 september